Neladalkib is a next-generation, brain-penetrant, ALK-selective inhibitor designed to overcome resistance to existing ALK-targeted therapies, including tumors harboring challenging resistance mutations such as G1202R. Its activity against both single and compound ALK resistance mutations positions it as a promising option for patients who progress on first-, second-, or third-generation ALK inhibitors. Reflecting its potential, the US FDA accepted Nuvalent’s NDA for neladalkib under Priority Review, with a PDUFA action date of November 27, 2026. The submission is supported by data from the global Phase I/II ALKOVE-1 trial in TKI-pretreated ALK-positive NSCLC, with updated efficacy and safety findings, along with preliminary data in TKI-naïve patients, presented at ASCO 2026.

Key Efficacy Result: 

Key Safety Result: 

• Neladalkib demonstrated a manageable and generally well-tolerated safety profile.

• The most common adverse events were transient liver enzyme elevations (ALT/AST increases), which were largely asymptomatic, low-grade, and reversible with dose interruption or reduction.

• The safety profile supports the drug's ALK-selective, TRK-sparing design, which aims to minimize off-target toxicities often seen with earlier-generation ALK inhibitors.

• No new safety signals were reported, and the overall tolerability compares favorably with currently available ALK inhibitors in heavily pretreated patients.

KOL insights

“Phase I/II ALKOVE-1 data build on the consistent characterization of neladalkib across preclinical and Phase I investigations. The data support neladalkib's potential to deliver on its design goals as an option for patients with ALK-positive NSCLC, including those whose disease progresses with brain metastases or resistance mutations, or who are unable to tolerate the currently available TKIs.” –Expert Opinion

“Nuvalent presents a unique near-term opportunity to advance multiple potential best-in-class product candidates for patients with cancer, backed by robust clinical experience demonstrating clear global medical need and enthusiasm.”–Expert Opinion

Conclusion-

The ALK-positive NSCLC treatment landscape is dominated by established next-generation ALK inhibitors, including alectinib, brigatinib, lorlatinib, and the recently approved ensartinib, all of which have demonstrated strong efficacy and CNS activity. However, resistance mutations and disease progression remain key challenges, creating opportunities for newer therapies. In 2025, the total market size of ALK NSCLC was around USD 1,200 million in the United States.

Neladalkib (NVL-655) enters a competitive but relatively mature market as a next-generation, brain-penetrant, ALK-selective inhibitor specifically designed to overcome resistance mutations, including G1202R, while minimizing off-target toxicities. Its primary competition includes approved ALK inhibitors such as lorlatinib, alectinib, brigatinib, and ensartinib, as well as emerging pipeline candidates like Foritinib (SAF-189s), Deulorlatinib (TGRX-326), and Ficonalkib. If its promising efficacy, intracranial activity, and favorable tolerability are confirmed in later-stage studies, neladalkib could emerge as a differentiated option for patients progressing on current ALK-targeted therapies.